2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Immunological Properties of Atopic Dermatitis-Associated Alopecia Areata

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Alopecia areata (AA) is regarded as a tissue-specific and cell-mediated autoimmune disorder. Regarding the cytokine balance, AA has been considered a type 1 inflammatory disease. On the other hand, AA often complicates atopic dermatitis (AD) and AD is regarded as type 2 inflammatory disease. However, the immunological aspects of AA in relation to AD are still poorly understood. Therefore, we aim to clarify the immunological properties of AD-associated AA. In this study, we performed comparative analysis of the expression of intracytoplasmic cytokines (IFN-γ, IL-4, and IL-13), chemokine receptors (CXCR3 and CCR4) in peripheral blood which were taken from healthy controls, non-atopic AA patients, AA patients with extrinsic AD, and AA patients with intrinsic AD by flowcytometric analysis. We also compared the scalp skin samples taken from AA patients with extrinsic AD before and after treatment with dupilumab. In non-atopic AA patients, the ratios of CD4+IFN-γ+ cells to CD4 +IL-4 + cells and CD4 +IFN-γ + cells to CD4 +IL-13 + cells were higher than those in AA patients with extrinsic AD. Meanwhile, the ratio of CD8 +IFN-γ + cells to CD8+IL-13+ cells was significantly higher in the non-atopic AA than in the healthy controls. In AA patients with extrinsic AD, the skin AA lesion showed dense infiltration of not only CXCR3+ cells but also CCR4 + cells around hair bulb before dupilumab treatment. However, after the treatment, the number of CXCR3 + cells had no remarkable change while the number of CCR4 + cells significantly decreased. These results indicate that the immunological condition of AA may be different between atopic and non-atopic patients and between extrinsic and intrinsic AD patients. Our study provides an important notion that type 2 immunity may participate in the development of AA in extrinsic AD patients. It may be considered that the immunological state of non-atopic AA is different from that of atopic AA.

          Related collections

          Most cited references50

          • Record: found
          • Abstract: found
          • Article: not found

          The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group.

          To test the reliability of the eczema area and severity index (EASI) scoring system by assessing inter- and intra-observer consistency. Training of evaluators, application, and assessment over 2 consecutive days. An academic center. Twenty adults and children with atopic dermatitis (AD); cohort 1 (10 patients > or = 8 years) and cohort 2 (10 patients < 8 years). None. The EASI was used by 15 dermatologist evaluators to assess atopic dermatitis in cohort 1 and cohort 2 on 2 consecutive days. Inter- and intraobserver reliability were analyzed. Overall intra-evaluator reliability of the EASI was in the fair-to-good range. Inter-evaluator reliability analyses indicated that the evaluators assessed the patients consistently across both study days. This study demonstrated that the EASI can be learned quickly and utilized reliably in the assessment of severity and extent of AD. There was consistency among the evaluators between consecutive days of evaluation. These results support the use of the EASI in clinical trials of therapeutic agents for AD.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Alopecia areata investigational assessment guidelines--Part II. National Alopecia Areata Foundation.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Dupilumab: A review of its use in the treatment of atopic dermatitis.

              Atopic dermatitis (AD) is a chronic, pruritic immune-mediated inflammatory dermatosis characterized by a T helper 2 (Th2) immune response phenotype and may be associated with systemic inflammation. Dupilumab is an interleukin 4 (IL-4) receptor α-antagonist that inhibits IL-4 and IL-13 signaling through blockade of the shared IL-4α subunit. Blockade of IL-4/13 is effective in reducing Th2 response. Dupilumab has recently been approved in the United States and Europe for the treatment of adult patients with moderate-to-severe AD. Clinical trials have shown that adults with moderate-to-severe AD who receive weekly or biweekly dupilumab injections have significantly improved clinical and patient-reported outcomes, including Eczema Area Severity Index, SCORing Atopic Dermatitis, Dermatology Life Quality Index, and itch Numeric Rating Scale scores. Concomitant use of topical corticosteroids along with dupilumab results in a greater improvement in signs and symptoms of AD than with use of dupilumab alone. Biomarker analyses show that dupilumab modulates the AD molecular signature and other Th2-associated biomarkers. Common adverse events reported in the clinical trials were nasopharyngitis, upper respiratory tract infection, injection site reactions, skin infections, and conjunctivitis. These were mild-to-moderate in nature, and overall rates of adverse events occurred with similar frequency between the treatment and placebo groups. There were no significant serious safety concerns identified in phase III clinical trials. Dupilumab, as monotherapy or with concomitant use of topical corticosteroids, can significantly improve clinical outcomes and quality of life in patients suffering from moderate-to-severe AD. Ongoing studies of dupilumab will help determine the clinical efficacy and safety profile of its long-term use.
                Bookmark

                Author and article information

                Contributors
                Role: Academic Editor
                Journal
                Int J Mol Sci
                Int J Mol Sci
                ijms
                International Journal of Molecular Sciences
                MDPI
                1422-0067
                05 March 2021
                March 2021
                : 22
                : 5
                : 2618
                Affiliations
                [1 ]Department of Dermatology, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan; reikok@ 123456hama-med.ac.jp (R.K.); 41237726@ 123456hama-med.ac.jp (N.M.); szawa@ 123456hama-med.ac.jp (S.N.); fujiyama@ 123456hama-med.ac.jp (T.F.); hontetsu@ 123456hama-med.ac.jp (T.H.)
                [2 ]Department of Dermatology, Seirei Hamamatsu General Hospital, Hamamatsu 431-3192, Japan; hanaishiho@ 123456gmail.com
                [3 ]Department of Cellular & Molecular Anatomy, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan; tokura@ 123456hama-med.ac.jp
                Author notes
                [* ]Correspondence: itoutai@ 123456hama-med.ac.jp ; Tel.: +81-53-435-2303; Fax: +81-53-435-2368
                Author information
                https://orcid.org/0000-0003-3553-796X
                Article
                ijms-22-02618
                10.3390/ijms22052618
                7961331
                33807704
                0c9ca2d5-8e31-436e-8646-47857fad6c90
                © 2021 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( http://creativecommons.org/licenses/by/4.0/).

                History
                : 05 February 2021
                : 03 March 2021
                Categories
                Article

                Molecular biology
                alopecia areata,extrinsic atopic dermatitis,intrinsic atopic dermatitis,il-13,ifn-γ

                Comments

                Comment on this article